Collagenase Clostridium Histolyticum /ML
ApprovedSmall molecule
Collagenase Clostridium Histolyticum /ML is one of 13 small molecule programs targeting Contracture. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Contracture
#DrugCompanyPhaseTrials
1Kenalog
BBausch Health Americas, Inc.
Phase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Xiaflex
GGrupo Espanol de Tumores Neuroendocrinos
Phase 2
Clostridial Collagenase Injectable
IIndiana Hand to Shoulder Center
Approved
Botulinum Toxin a
GSKPhase 2
Collagenase Clostridium Histolyticum /ML
TTampere University
Approved
Accolate
Alnylam PharmaceuticalsPhase 2
AA4500
Endo PharmaceuticalsPhase 3
Ketotifen Fumarate
Tanabe Pharma CorporationPhase 3
Decadron
AAspen Global Incorporated
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- TTampere University